Actinogen Medical is focused on the treatment of Alzheimer’s Disease and mild cognitive impairment, a transitional stage of cognitive impairment between normal aging and the more serious conditions of Alzheimer’s and dementia. It is developing a novel drug to treat the condition and other age-related neurodegenerative diseases. The lead candidate drug Xanamem™, blocks the development of cortisol which appears to contribute to cognitive impairment and neurological plaques. The company is currently undertaking a second Phase I multiple ascending dose trial in humans with results in mid-2015 and plans to undertake a Phase II study in late 2015. Actinogen was previously focused on antimicrobial and anti-cancer early stage drug discovery.